Perception of the impact of intravenous biological treatment on the work and professional environment in patients with inflammatory bowel disease
Gastroenterol Hepatol. 2024 May 7:502193.
doi: 10.1016/j.gastrohep.2024.502193.
Online ahead of print.
[Article in
English,
Spanish]
Authors
Carlos González Muñoza
1
, Cristina Gely
1
, Jordi Gordillo
1
, Margalida Calafat
2
, Federico Bertoletti
1
, Fiorella Cañete
2
, Míriam Mañosa
2
, Alberto López Faba
1
, Paola Torres
3
, Eugeni Domènech
4
, Esther Garcia Planella
5
Affiliations
- 1 Servicio de Patología Digestiva, Hospital Santa Creu i Sant Pau Barcelona, Spain.
- 2 Servicio de Aparato Digestivo, Hospital Universitari Germans Trias i Pujol Badalona, Spain; CIBEREHD, Spain.
- 3 Servicio de Aparato Digestivo, Hospital Universitari Germans Trias i Pujol Badalona, Spain.
- 4 Servicio de Aparato Digestivo, Hospital Universitari Germans Trias i Pujol Badalona, Spain; CIBEREHD, Spain; Departament de Medicina, Universitat Autònoma de Barcelona, Spain.
- 5 Servicio de Patología Digestiva, Hospital Santa Creu i Sant Pau Barcelona, Spain. Electronic address: egarciapl@santpau.cat.
No abstract available
Keywords:
administration route; inflammatory bowel diseasebio; infliximab; logics.